Full Text
PND27 ESTIMATING MARGINAL COST-EFFECTIVENESS USING A PERSON-LEVEL NET BENEFITS APPROACH WITH AN APPLICATION TO DISEASE-MODIFYING DRUGS IN MULTIPLE SCLEROSIS

Abstract

Authors

MG Brown C Skedgel VA Hicks IS Sketris JD Fisk

Back to Volume 10, Issue 6
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×